Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt (RIG2) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt (RIG2) has a cash flow conversion efficiency ratio of 0.040x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€52.44 Billion ≈ $61.30 Billion USD) by net assets (€1.30 Trillion ≈ $1.52 Trillion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See net asset quality index of Richter Gedeon Vegyészeti Gyár Nyilvános to measure how much of total assets are equity-financed.
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt - Cash Flow Conversion Efficiency Trend (2013–2025)
This chart illustrates how Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check RIG2 cash to earnings ratio to evaluate the quality of earnings relative to operating cash generation.
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Lotes Co Ltd
TW:3533
|
0.037x |
|
Wallenius Wilhelmsen Logistics ASA
OL:WAWI
|
0.135x |
|
Chime Financial, Inc. Class A Common Stock
NASDAQ:CHYM
|
0.061x |
|
Lumen Technologies Inc
NYSE:LUMN
|
0.114x |
|
Informatica Inc
NYSE:INFA
|
0.061x |
|
The Swatch Group AG
SW:UHR
|
0.028x |
|
Nkt A/S
NYSE:NRKBY
|
0.025x |
|
Jindal Stainless Limited
NSE:JSL
|
0.110x |
Annual Cash Flow Conversion Efficiency for Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt (2013–2025)
The table below shows the annual cash flow conversion efficiency of Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt from 2013 to 2025. For the full company profile with market capitalisation and key ratios, see Richter Gedeon Vegyészeti Gyár Nyilvános market cap and net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €1.40 Trillion ≈ $1.64 Trillion |
€276.40 Billion ≈ $323.14 Billion |
0.197x | -7.91% |
| 2024-12-31 | €1.30 Trillion ≈ $1.52 Trillion |
€279.37 Billion ≈ $326.61 Billion |
0.214x | +67.87% |
| 2023-12-31 | €1.14 Trillion ≈ $1.34 Trillion |
€145.84 Billion ≈ $170.50 Billion |
0.128x | -26.81% |
| 2022-12-31 | €1.06 Trillion ≈ $1.24 Trillion |
€184.93 Billion ≈ $216.20 Billion |
0.174x | +15.06% |
| 2021-12-31 | €923.02 Billion ≈ $1.08 Trillion |
€139.90 Billion ≈ $163.56 Billion |
0.152x | -7.60% |
| 2020-12-31 | €813.94 Billion ≈ $951.58 Billion |
€133.52 Billion ≈ $156.10 Billion |
0.164x | +21.07% |
| 2019-12-31 | €724.87 Billion ≈ $847.45 Billion |
€98.21 Billion ≈ $114.82 Billion |
0.135x | -7.41% |
| 2018-12-31 | €685.75 Billion ≈ $801.71 Billion |
€100.34 Billion ≈ $117.31 Billion |
0.146x | +16.02% |
| 2017-12-31 | €664.02 Billion ≈ $776.31 Billion |
€83.75 Billion ≈ $97.91 Billion |
0.126x | +11.08% |
| 2016-12-31 | €681.87 Billion ≈ $797.18 Billion |
€77.42 Billion ≈ $90.51 Billion |
0.114x | -26.13% |
| 2015-12-31 | €618.39 Billion ≈ $722.96 Billion |
€95.05 Billion ≈ $111.12 Billion |
0.154x | +38.81% |
| 2014-12-31 | €561.73 Billion ≈ $656.72 Billion |
€62.20 Billion ≈ $72.72 Billion |
0.111x | -17.46% |
| 2013-12-31 | €551.20 Billion ≈ $644.41 Billion |
€73.94 Billion ≈ $86.45 Billion |
0.134x | -- |
About Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
Gedeon Richter PLC researches, develops, manufactures, markets, and sells pharmaceutical products. It offers women's healthcare products for contraceptives, endometriosis, fertility, menopause, vaginal infections, and uterine fibroids; and Femtech, a digital therapeutic solution to enhance women's lives. It also provides central nervous system products, such as products for the treatment of chron… Read more